Skip to main content
    B

    Beam Therapeutics Inc (BEAM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.94
    -1.89 (-8.28%)

    Market Cap: $2.36B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Beam Therapeutics Inc (BEAM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Beam Therapeutics (BEAM) to earn -$4.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $38.51M. Of 15 analysts, 13 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 87% of the ratings.

    RatingAnalystsShare
    Strong Buy16.7%
    Buy1280.0%
    Hold213.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 18.9%.

    Fiscal year ending Dec 31, 2026
    -$4.53
    EPS consensus, revenue $38.51M
    Fiscal year ending Dec 31, 2027
    -$5.01
    EPS consensus, revenue $31.22M
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.53-$4.73 to -$3.7614$38.51M$32.84M to $48.50M13
    Dec 31, 2027-$5.01-$6.15 to -$3.5615$31.22M$1.23M to $50.00M13

    Quarterly Estimates

    The EPS consensus rises from -$1.25 for the quarter ending Dec 31, 2026 to -$1.24 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.25-$1.32 to -$1.1917$6.30MN/A16
    Mar 31, 2027-$1.24-$1.25 to -$1.232$400000$300000 to $5000002

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202605
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.45.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.53-$4.42-$4.45-$4.45-$4.45N/A
    Fiscal year ending Dec 31, 2027-$5.01-$4.76-$4.74-$4.74-$4.74N/A
    Quarter ending Mar 31, 2027-$1.24-$1.21-$1.20-$1.20-$1.20N/A

    Frequently Asked Questions About BEAM

    What is the BEAM stock forecast?

    Consensus analyst estimates put Beam Therapeutics's EPS at -$4.53 for the fiscal year ending Dec 31, 2026, on revenue of $38.51M. The consensus rating from 15 analysts is Buy.

    How do analysts rate BEAM stock?

    Of 15 analysts covering Beam Therapeutics, 1 rates it Strong Buy, 12 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BEAM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.53, with estimates from -$4.73 to -$3.76 from 14 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.01, with estimates from -$6.15 to -$3.56 from 15 analysts.

    What revenue do analysts expect from Beam Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $38.51M, with estimates from $32.84M to $48.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $31.22M, with estimates from $1.23M to $50.00M.

    How many analysts cover BEAM?

    15 analysts rate Beam Therapeutics stock, and 14 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.